User menu

Mapping the QLQ-C30 quality of life cancer questionnaire to EQ-5D patient preferences

Bibliographic reference Crott, Ralph ; Briggs, Andrew. Mapping the QLQ-C30 quality of life cancer questionnaire to EQ-5D patient preferences. In: The European Journal of Health Economics, Vol. 11, no. 4, p. 427-434 (2010)
Permanent URL
  1. Efficace, F., Bottomley, A., Osoba, D., Gotay, C., Flechtner, H., D’haese, S., Zurlo, A.: Beyond the development of health-related quality-of-life (HRQOL) measures: a checklist for evaluating HRQOL outcomes in cancer clinical trials—does HRQOL evaluation in prostate cancer research inform clinical decision making? J. Clin. Oncol. 21(18), 3502–3511 (2003)
  2. Fayers, P.M., Aaronson, N.K., Bjordal, K., Groenvold, M., Curran, D., Bottomley, A., on behalf of the EORTC Quality of Life Group: The EORTC QLQ-C30 scoring manual, 3rd edn. European Organisation for Research and Treatment of Cancer (EORTC), Brussels (2001)
  3. Gotay, C.C., Kawamoto, C.T., Bottomley, A., Efficace, F.: The prognostic significance of patient-reported outcomes in cancer clinical trials. J. Clin. Oncol. 26(8), 1355–1363 (2008)
  4. Therasse, P., Mauriac, L., Welnicka-Jaskiewicz, M., Bruning, P., Cufer, T., Bonnefoi, H., Tomiak, E., Pritchard, K.I., Hamilton, A., Piccart, M.J.: Final results of a randomized phase III trial comparing cyclophosphamide, epirubicin, and fluorouracil with a dose-Intensified epirubicin and cyclophosphamide–filgrastim as neoadjuvant treatment in locally advanced breast cancer: an EORTC-NCIC-SAKK multicenter study. J. Clin. Oncol. 21(5), 843–850 (2003)
  5. EQ-5D Value sets: inventory, comparative review and user guide. In: Szende, A., Oppe, M., Devlin, N. (Eds.) EuroQol Group Monographs. Springer, Dordrecht (2007), ISBN 978-1402055102
  6. Efficace, F., Therasse, P., Piccart, M.J., Coens, C., Van Steen, K., Welnicka-Jaskiewicz, M., Cufer, T., Dyczka, J., Lichinitser, M., Shepherd, L., de Haes, H., Sprangers, M.A., Bottomley, A.: Health-related quality of life parameters as prognostic factors in a nonmetastatic breast cancer population: an international multicenter study. J. Clin. Oncol. 22(16), 3381–3388 (2004)
  7. Bottomley, A., Therasse, P., Piccart, M., Efficace, F., Coens, C., Gotay, C., Welnicka-Jaskiewicz, M., Dyczka, L.M.J., Cufer, T., Lichinitser, M.R., Schornagel, J.H., Bonnefoi, H., Shepherd, L., For the European Organisation for Researchand Treatment of Cancer Breast Cancer Group, the National Cancer Institute of Canada, Swiss Group for Clinical Cancer Research: Health-related quality of life in survivors of locally advanced breast cancer: an international randomised controlled phase III trial. Lancet Oncol 6, 287–294 (2005)
  9. Dolan, P.: Modeling valuations for EuroQol health states. Med. Care 35(11), 1095–1108 (1997)
  10. Dolan, P., Gudex, C., Kind, P., Williams, A.: The time trade-off method: results from a general population study. Health Econ. 5, 141–154 (1996)
  11. Szende, A., Oppe, M., Devlin, N.: EQ-5D value sets, inventory, comparative review and user guide. Springer, Berlin (2006)
  12. McKenzie, L., Van der Pol, M.: Mapping the EORTC QLQ C-30 onto the EQ-5D instrument: the potential to estimate QALY’s without generic preference data. Value Health 12(1), 167–171 (2009)
  13. Gray, A.M., Rivero-Arias, O., Clarke, P.M.: Estimating the association between SF-12 responses and EQ-5D utility values by response mapping. Med. Decis. Mak. 26, 18–29 (2006)
  14. Brazier, J.E., Yang, Y., Tsuchiya, A., Rowen, D.L.: A review of studies mapping (or cross walking) non-preference based measures of health to generic preference-based measures. Eur. J. Health Econ. (2009). doi: 10.1007/s10198-009-0168-z
  15. Peat, J., Barton, B.: Medical statistics: a guide to data analysis and critical appraisal, 1st edn., p. 150. BMJ Books, Oxford (2005)
  16. Hardin, J.W., Hilbe, J.M.: Generalized estimation equations. Chapman & Hall/CRC, Boca Raton (2003)
  17. Doornebosch, P.G., Tollenaar, R.A., Gosselink, M.P., Stassen, L.P., Dijkhuis, C.M., Schouten, W.R., van de Velde, C.J., de Graaf, E.J.: Quality of life after transanal endoscopic microsurgery and total Mesorectal excision in early rectal cancer. Colorectal Dis. 9(6), 553–558 (2007)
  18. Gosselink, M.P., Busschbach, J.J., Dijkhuis, C.M., Stassen, L.P., Hop, W.C., Schouten, W.R.: Quality of life after total mesorectal excision for rectal cancer. Colorectal Dis. 8(1), 15–22 (2006)
  19. Krabbe, P.F., Peerenboom, L., Langenhoff, B.S., Ruers, T.J.: Responsiveness of the generic EQ-5D summary measure compared to the disease-specific EORTC QLQ C-30. Qual. Life Res. 13(7), 1247–1253 (2004)
  20. Krahn, M., Bremner, K.E., Tomlinson, G., Ritvo, P., Irvine, J., Naglie, G.: Responsiveness of disease-specific and generic utility instruments in prostate cancer patients. Qual. Life Res. 16(3), 509–522 (2007)
  21. Wu, E.Q., Mulani, P., Farrell, M.H., Sleep, D.: Mapping FACT-P and EORTC QLQ-C30 to patient health status measured by EQ-5D in metastatic hormone-refractory prostate cancer patients. Value Health 10(5), 408–414 (2007)
  22. Kind, P.: Measuring the quality of life on cancer: an index based on QLQ-C30 presentation, ASCO 2005 Annual Meeting, Category Health Services Research, abstract published in JCO, vol. 23, No. 16S, Part I of II, June 1 Supplement, 2005:6013
  23. Kontodimopoulos, N., Aletras, V.H., Paliouras, D.: Mapping the cancer-specific EORTC QLQ-C30 to the preference-based EQ-5D, SF-6D and 15D instruments. Value Health, 12(8), 1151–1157 (2009)
  24. McKenzie, L., Van der Pol, M.: Mapping the EORTC QLQ C-30 onto the EQ-5D instrument: the potential to estimate QALY’s without generic preference DATA. Value Health 12(1), 167–171 (2009)
  25. Pickard, A.S., Shaw, J.W., Lin, H.W., Trask, P.C., Aaronson, N., Lee, T.A., Cella, D.: A patient-based utility measure of health for clinical trials of cancer therapy based on the European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire. Value Health 12(6), 977–988 (2009)
  26. Jang, R.W., Mittmann, N., Isogai, P., Bradbury, P.A., Leighl, N.B.: Derivation of utility values from EORTC QLQ-C30 values in lung cancer, ISPOR 2008, Toronto (Poster abstract PCN78). Value Health 11(3), A77 (2008)
  27. Petrillo, J., Cairns, J.: Concerting condition-specific measures into preference-based outcomes for use in economic evaluation. Expert Rev. Pharmacoecon. Outcomes Res. 8(5), 453–461 (2008)
  28. Bleeker, S.E., Moll, H.A., Steyerberg, E.W., Donders, A.R., Derksen-Lubsen, G., Grobbee, D.E., Moons, K.G.: External validation is necessary in prediction research: a clinical example. J. Clin. Epidemiol. 56(9), 826–832 (2003)
  29. Steyerberg, E.W., Bleeker, S.E., Moll, H.A., Grobbee, D.E., Moons, K.G.: Internal and external validation of predictive models: a simulation study of bias and precision in small samples. J. Clin. Epidemiol. 56(5), 441–447 (2003)
  30. Luo, N., Johnson, J.A., Shaw, J.W., Coons, S.J.: A comparison of the EQ-5D index scores derived from the US and UK population-based scoring functions. Med. Decis. Mak. 27, 321–326 (2007)
  31. Chay, K.Y., Powell, J.L.: Semiparametric censored regression models. J. Econ. Perspect. 15(4), 29–42 (2001)
  32. Sullivan, P., Ghushchyan, V.: Preference-based EQ-5D index scores for chronic conditions in the United States. Med. Decis. Mak. 26, 410–420 (2006)